Sommetrics has been selected to be one of five companies to present at the airways symposium of the Respiratory Innovation Summit in Dallas on May 17, 2019. This Summit is a yearly event held in advance of the American Thoracic Society’s International meeting which brings together clinicians, innovators and investors focused on new approaches for treating widespread and crippling lung and airway diseases.
“This is an ideal venue for highlighting the clinical progress made in establishing our aerSleep™ system as a treatment option for obstructive sleep apnea (OSA),” remarked Dr. Richard Rose, President, CEO and Chief Medical Officer of Sommetrics. ”It is particularly appropriate to discuss aerSleep™ in the context of airways disease since OSA is now believed to be the commonest chronic respiratory disorder worldwide – more prevalent than asthma or COPD. Yet, only a small fraction of individuals with OSA are currently receiving effective therapy. It is this extraordinary medical need that our aerSleep™ system addresses.”
The aerSleep™ system consists of a comfortable silicone collar fitted on the front of the neck which holds the airway open via the application of mild external negative pressure delivered by a quiet, integrated vacuum pump. This system has a number of advantages over conventional sleep apnea therapies in that it is non-invasive, simple to use and maintain, highly portable and well tolerated by the majority of users. An earlier version of aerSleep has previously received market clearance from Health Canada.
Source: Business Wire